Press release - 10/04/2026 Lancet Countdown Europe: New Report on Health and Climate Change Europe’s dependence on fossil fuels is not only making the continent economically and politically vulnerable, it also has consequences for the population’s health. Growing air pollution, heat damage and the climate-related spread of infectious diseases are looming, warns the 2026 Europe Report of the Lancet Countdown on Health and Climate Change, which its co-directors are about to present to the public. https://www.gesundheitsindustrie-bw.de/en/article/press-release/lancet-countdown-europe-new-report-health-and-climate-change
Press release - 07/04/2026 The molecular research “booster” evolves: SIMPLAIX collaboration starts the next phase Computer simulations and Artificial Intelligence are the main pillars of the “SIMPLAIX” collaboration, initiated by the Heidelberg Institute for Theoretical Studies (HITS). Together with colleagues from Heidelberg University and Karlsruhe Institute of Technology, HITS researchers are addressing challenges in the simulation of biomolecules and molecular materials by pooling their expertise in multiscale computer simulation and machine learning. https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-research-booster-evolves-simplaix-collaboration-starts-next-phase
Press release - 07/04/2026 The molecular research “booster” evolves: SIMPLAIX collaboration starts the next phase Computer simulations and Artificial Intelligence are the main pillars of the “SIMPLAIX” collaboration, initiated by the Heidelberg Institute for Theoretical Studies (HITS). Together with colleagues from Heidelberg University and Karlsruhe Institute of Technology, HITS researchers are addressing challenges in the simulation of biomolecules and molecular materials by pooling their expertise in multiscale computer simulation and machine learning. https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-research-booster-evolves-simplaix-collaboration-starts-next-phase
Press release - 10/04/2026 Vitamin B12 Found to Drive Inherited Behavioural Changes Across Generations A team of researchers from the Department of Integrative Evolutionary Biology at the Max Planck Institute for Biology Tübingen has discovered that vitamin B12 plays a key role in transmitting behavioural memories across generations. The study shows for the first time how a nutrient from the diet can, without altering the genome, influence behaviour over multiple generations.https://www.gesundheitsindustrie-bw.de/en/article/press-release/vitamin-b12-found-drive-inherited-behavioural-changes-across-generations
Press release - 02/04/2026 Pocket-sized biomedical technology to become smarter Volkswagen Foundation supports mobile health expert Professor Walter Karlen The Volkswagen Foundation is supporting the Ulm scientist Professor Walter Karlen with more than 940,000 euros from the funding initiative "Momentum - funding for first-time researchers". The engineer has headed the Institute of Biomedical Engineering at Ulm University since 2021. Karlen conducts research in the field of mobile health on so-called Medicine Wearables, i.e. portable technology for recording health data. https://www.gesundheitsindustrie-bw.de/en/article/press-release/pocket-sized-biomedical-technology-become-smarter-volkswagen-foundation-supports-mobile-health-expert-professor-walter-karlen
Press release - 10/04/2026 New study identifies clinically relevant changes in airway wall thickness in COPD and at-risk individuals A recent study published in the European Respiratory Journal provides important new insights into the early identification and monitoring of chronic obstructive pulmonary disease (COPD). The focus is on airway wall thickness as an imaging marker for structural remodeling processes in the lungs.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-study-identifies-clinically-relevant-changes-airway-wall-thickness-copd-and-risk-individuals
Press release - 09/04/2026 “Positions, please!” For over a decade, a class of drugs called BET inhibitors has been tested in cancer trials with high expectations. The biology looked promising. Many cancers depend on oncogenes that (BET) proteins help activate, so blocking BET proteins should slow tumor growth. In the lab, it often did. In patients, results were mostly disappointing: limited responses, significant side effects, and no clear way to predict which tumors would respond at all.https://www.gesundheitsindustrie-bw.de/en/article/press-release/positions-please